@entity0 ( @entity0 ), devoid of hormone receptors and @entity1 epidermal growth-factor receptor-2/ @entity1722 expression, bring about poor prognosis and induce a high rate of systematic @entity3 . The ineffectiveness of current therapies on @entity0 could be attributed to the lack of efficient targeted therapy. @entity1311 ( @entity4045 ) is considered one of first-line chemotherapeutics for TNBC treatment but, due to its low aqueous solubility and nonspecific accumulation, results in poor antitumor efficacy. The present study is aimed at enhancing the chemotherapeutic potency of @entity4045 by improving the stability and targeting efficiency of @entity4045 -loaded nanoparticulate drug carriers. Here, @entity4045 was incorporated in nontoxic and endogenous material, human @entity2313 (HSA), via an innovative @entity1520 reduction method to construct HSA-based @entity4045 nanoparticle (HSA- @entity4045 NP) to not only realize redox-responsive drug release but also improve in vivo stability. Besides, W peptide was selected as a target ligand to be conjugated with HSA- @entity4045 NP for endowing active targeting ability. The resulting Wpep-HSA- @entity4045 NP possessed a spherical structure (118 nm), 9.87% drug-loading content, and 86.3% entrapment efficiency. An in vitro drug release test showed that @entity4045 release from Wpep-HSA- @entity4045 NP was of a redox-responsive manner. Furthermore, cellular uptake of Wpep-HSA- @entity4045 NP was significantly enhanced, exhibiting the improved antiproliferation and antitube formation effects of @entity4045 in vitro. In comparison with those commercial formulations and conventional HSA NP, Wpep-HSA- @entity4045 NP exhibited better pharmacokinetic behaviors and @entity5 homing characteristics. The antitumor efficacy of Wpep-HSA- @entity4045 NP was further confirmed by the strong pro-apoptotic effect and reduced @entity5 burden. In a word, this evidence highlighted the proof of concept for Wpep-HSA NP as a promising conqueror to the ineffectiveness of TNBC therapy.

Biomimetic Human XXXX Nanoparticle for Efficiently Targeting Therapy to Metastatic @entity0 .

@entity1 :: ('9606', 'Species') :: ['human'] @entity2313 :: ('213', 'Gene') :: ['serum albumin'] @entity0 :: ('MESH:D001943', 'Disease') :: ['TNBCs', 'Triple-negative breast cancers'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['Paclitaxel'] @entity4045 :: ('D010852', 'Chemical') :: ['PTX'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity1520 :: ('CHEBI:48343', 'Chemical') :: ['disulfide'] @entity1722 :: ('2064', 'Gene') :: ['Neu']
@entity2313 :: (213,Gene) :: ['Serum Albumin']
